ReviewGut microbes2017
Fecal microbial transplantation as a therapeutic option in patients colonized with antibiotic resistant organisms.
Review in Gut microbes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial.Microbiome · 2020Trial
- Fecal microbiota transplantation in pigs: current status and future perspective.Animal microbiome · 2025Review
- Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection.The Journal of infectious diseases · 2025Article
- Rational Design of Live Biotherapeutic Products for the Prevention ofbioRxiv : the preprint server for biology · 2024Article
- Cost-effectiveness of Fecal Microbiota Transplantation for First Recurrent Clostridioides difficile Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Faecal microbiota transplantation reduces amounts of antibiotic resistance genes in patients with multidrug-resistant organisms.Antimicrobial resistance and infection control · 2022Article
- Multi-omics investigation ofeLife · 2022Article
- Orchestrating the fecal microbiota transplantation: Current technological advancements and potential biomedical application.Frontiers in medical technology · 2022Review
- Gut Microbiome Modulation and Faecal Microbiota Transplantation Following Allogenic Hematopoietic Stem Cell Transplantation.Cancers · 2021Review
- Gut microbiota in antiviral strategy from bats to humans: a missing link in COVID-19.Science China. Life sciences · 2021Review
- Novel Insights Into Pathogenesis and Therapeutic Strategies of Hepatic Encephalopathy, From the Gut Microbiota Perspective.Frontiers in cellular and infection microbiology · 2021Review
- Article
- Cultivation and Genomics Prove Long-Term Colonization of Donor's Bifidobacteria in RecurrentFrontiers in microbiology · 2020Article
- Impact of Microbiota Transplant on Resistome of Gut Microbiota in Gnotobiotic Piglets and Human Subjects.Frontiers in microbiology · 2020Article
- Improvement of Good's syndrome by fecal microbiota transplantation: the first case report.The Journal of international medical research · 2019Article
- The success of fecal microbial transplantation inGut microbes · 2019Article
- Fecal microbiota transplantation as a tool to treat and reduce susceptibility to disease in animals.Veterinary immunology and immunopathology · 2018Review
- Antimicrobial Resistance Gene Acquisition and Depletion Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
- Fecal microbiota transplantation-early steps on a long journey ahead.Gut microbes · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Despite increasing interest in fecal microbiota transplantation (FMT), its full therapeutic potential has yet to be determined. Since its increase in popularity, FMT has been shown to be highly effective in the treatment of both Clostridium difficile infection (CDI) and its recurrent form. Interest in FMT now expands well beyond the treatment of CDI to other processes with known associations to the microbiota such as antibiotic resistant infections, inflammatory bowel disease (IBD), hepatic encephalopathy, neuropsychiatric disorders, and metabolic disease. The rampant use and misuse of antibiotics in both medicine and agriculture has resulted in an increase in antibiotic resistant organisms which pose a significant risk to human health. The purpose of this commentary is to address the general issue of antibiotic resistance in the human microbiota and the restorative potential of FMT in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.